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Abstract
Introduction: Lower gelsolin levels have been associated with the severity and poor outcome of critical illness.
Nevertheless, their link with clinical outcomes of aneurysmal subarachnoid hemorrhage is unknown. Therefore, we
aimed to investigate the relationship between plasma gelsolin levels and clinical outcomes in patients with
aneurysmal subarachnoid hemorrhage.
Methods: A total of 262 consecutive patients and 150 healthy subjects were included. Plasma gelsolin levels were
measured by enzyme-linked immunosorbent assay. Mortality and poor long-term outcome (Glasgow Outcome
Scale score of 1-3) at 6 months were recorded.
Results: Plasma gelsolin levels on admission were substantially lower in patients than in healthy controls
(66.9 (26.4) mg/L vs. 126.4 (35.4) mg/L, P < 0.001), and negatively associated with World Federation of Neurological
Surgeons score (r = -0.554, P < 0.001) and Fisher score (r = -0.538, P < 0.001), and identified as an independent
predictor of poor functional outcome (odds ratio, 0.957; 95% confidence interval (CI), 0.933-0.983; P = 0.001) and
death (odds ratio, 0.953; 95% CI, 0.917-0.990; P = 0.003) after 6 months. The areas under the ROC curve of gelsolin
for functional outcome and mortality were similar to those of World Federation of Neurological Surgeons score
and Fisher score (all P > 0.05). Gelsolin improved the predictive values of World Federation of Neurological
Surgeons score and Fisher score for functional outcome (both P < 0.05), but not for mortality (both P > 0.05).
Conclusions: Gelsolin levels are a useful, complementary tool to predict functional outcome and mortality
6 months after aneurysmal subarachnoid hemorrhage.
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Introduction
Plasma gelsolin is the extracellular isoform of a ubiquitous
cytoplasmic actin-binding protein, gelsolin, which med-
iates cell shape changes and motility [1]. Plasma gelsolin is
associated with the severity and outcome of critical illness,
and therefore, has been proposed as a prognostic marker
in acute illness [2-11]. Recently, it has been reported that
plasma gelsolin levels were also decreased in the patients
with traumatic brain injury [12], ischemic stroke [13], and
intracerebral hemorrhage [14]; in these groups of patients,
low gelsolin levels were highly predictive for mortality.
Gelsolin has been also found to be depleted in the periph-
eral blood of patients with aneurysmal subarachnoid
hemorrhage (SAH) [15]. However, no published informa-
tion exists to date about the correlation of gelsolin with
outcome after aneurysmal SAH. The present study aimed
to investigate this correlation and to analyze the usefulness
of gelsolin as a predictor of long-term functional outcome
and mortality in aneurysmal SAH.
Materials and methods
Study population
Between June 2008 and August 2011, all patients with
aneurysmal SAH confirmed by computed tomography
(CT) angiography with or without digital subtraction
angiography who were admitted to Department of Neuro-
surgery, The First Affiliated Hospital, School of Medicine,
Zhejiang University were evaluated in the study. Inclusion
criteria were clinical history of SAH within the last 24 h
before admission and the treatment by surgery or coiling
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within 48 h after admission. Exclusion criteria were
rebleeding after admission, aged <18 years, existing pre-
vious head trauma, neurological disease, use of antiplatelet
or anticoagulant medication, presence of other prior sys-
temic diseases including uremia, liver cirrhosis, malig-
nancy, chronic heart or lung disease, diabetes mellitus,
and hypertension. Healthy individuals were evaluated as
controls if they presented to our hospital and had blood
collected as part of medical examination in May 2011. The
study was conducted in accordance with the guidelines
approved by the Human Research Ethics Committee at
The First Affiliated Hospital, School of Medicine, Zhejiang
University. Written informed consent was obtained from
the study subjects or their relatives.
Clinical and radiological assessment
At admission, clinical severity was assessed using the
World Federation of Neurological Surgeons (WFNS)
score as follows: 1 = Glasgow Coma Scale (GCS) score of
15, no motor deficit; 2 = GCS score of 13-14, no motor
deficit; 3 = GCS score of 13-14 and any motor deficit or
aphasia; 4 = GCS score of 7-12, with or without motor
deficit; and 5 = GCS of 3 to 6, with or without motor def-
icit [16]. The initial CT was classified according to the
modified Fisher score as follows: grade 1 = no subarach-
noid blood; grade 2 = broad diffusion of subarachnoid
blood; grade 3 = with clots or thick layers of subarach-
noid blood; grade 4 = intraventricular hemorrhage or
intracerebral hematoma, no clot; and grade 5 = intraven-
tricular hemorrhage or intracerebral hematoma with clot
[17]. All CT scans were performed according to the neu-
roradiology department protocol. Investigators who read
them were blinded to clinical information.
Patient management
The type of treatment (surgery or coiling) was decided
according to both location and size of the aneurysm by the
neurosurgeon and the neuroradiologist. All patients
received intravenous Nimodipine at a dose of 2 mg/h from
admission until at least day 14, except during periods of
uncontrolled increased intracranial pressure during which
intravenous Nimodipine was discontinued. Seizures were
systematically prevented by Sodium Valproate (200 mg × 3,
per os). After surgery or coiling, patients were managed
with ‘triple H’ therapy (hypertension with a mean arterial
pressure goal >100 mm Hg, hypervolemia, and hemodilu-
tion with a goal hematocrit of 30) through 12 days after
hemorrhage. An external ventricular drain was inserted in
case of hydrocephalus on CT and in patients with a high
WFNS grade (WFNS score of 3 to 5). Increased intracranial
pressure was treated by cerebrospinal fluid drainage,
mechanical ventilation, reinforcement of sedation, and,
rarely, moderate hypothermia. CT was performed whenever
clinical deterioration occurred to search for secondary com-
plications such as hydrocephalus or ischemia.
Clinical onset of cerebral vasospasm was defined as the
acute onset of a focal neurologic deficit or a change in the
GCS score of 2 or more points. All suspected cases of cer-
ebral vasospasms were confirmed by CT angiography and
were then taken to the interventional radiology suite for
cerebral angiography. Each vasospasm episode was treated
with intra-arterial administration of Nimodipine as
recently described. This therapy was repeated if necessary.
Balloon angioplasty was used as a second-line therapy
when Nimodipine was judged insufficient.
Determination of gelsolin in plasma
The informed consents were obtained from study popula-
tion or family members in all cases before the blood were
collected. Venous blood in the healthy individuals or the
patients was drawn at study entry or on admission. The
blood samples were immediately placed into sterile EDTA
test tubes and centrifuged at 1,500 g for 20 min at 4°C to
collect plasma. Plasma was stored at -70°C until assayed.
The concentration of gelsolin in plasma was analyzed by
enzyme-linked immunosorbent assay (ELISA) using com-
mercial kits (CoTimes, Beijing, China) in accordance with
the manufactures’ instructions. Intra-assay and inter-assay
coefficients of variation were 4.2% and 6.8%, respectively.
The blood samples were run in duplicate. Researchers
running ELISAs were blinded to all patient details.
Endpoint
Participants were followed up until death or completion of
6 months after SAH. The endpoints were unfavorable out-
come and death after 6 months. The functional outcome
was defined by Glasgow outcome scale (GOS) score. GOS
was defined as follows: 1 = death; 2 = persistent vegetative
state; 3 = severe disability; 4 = moderate disability; and 5 =
good recovery [18]. GOS scores were dichotomized in
favorable and unfavorable outcomes (GOS of 4-5 vs. GOS
of 1-3). For follow-up, structured telephone interviews
were performed by one doctor who was blinded to clinical
information and gelsolin levels.
Statistical analysis
Statistical analysis was performed with SPSS 10.0 (SPSS
Inc., Chicago, IL, USA) and MedCalc 9.6.4.0. (MedCalc
Software, Mariakerke, Belgium). The normality of data dis-
tribution was assessed by the Kolmogorovor-Smirnov test
or Shapiro-Wilk test. All values are expressed as median
(interquartile range), mean ± standard deviation or counts
(percentage) unless otherwise specified. Comparisons were
made by using: (1) chi-square test or Fisher exact test for
categorical data; (2) unpaired Student t test for continuous
normally distributed variables; and (3) the Mann-Whitney
Pan et al. Critical Care 2013, 17:R149
http://ccforum.com/content/17/4/R149
Page 2 of 10
U-test for continuous non-normally distributed variables.
Correlations of gelsolin with other variables were assessed
by Spearman’s correlation coefficient. The relations of gel-
solin to the poor functional outcome (GOS 1-3) and death
were assessed in a logistic-regression model. For multivari-
ate analysis, we included the significantly different out-
come predictors as assessed in univariate analysis. A ROC
curve was configured to establish the cutoff point of
plasma gelsolin with the optimal sensitivity and specificity
for predicting the poor functional outcome (GOS 1-3) and




During the recruitment period, 308 patients were
admitted with an initial diagnosis of aneurysmal SAH,
269 (87.3%) patients fulfilled the inclusion criteria and
exclusion criteria, and adequate data on admission and
follow-up were available for 262 individuals (112 men
and 150 women) (85.1%) who were finally included in the
analysis. Table 1 summarized the other demographic,
clinical, laboratory and radiological data from baseline
CT scans of the patients. A control group consisted of
150 healthy individuals. The intergroup differences of
patients and healthy controls in the age and sex were not
statistically significant (both P > 0.05).
The change of plasma gelsolin level in SAH patients
Plasma gelsolin values are continuous non-normally distrib-
uted variables. Therefore, all values are expressed as median
(interquartile range). Using the Mann-Whitney U-test, the
admission gelsolin levels were significantly decreased in all
patients (66.9 (26.4) mg/L), survivals (70.3 (25.5) mg/L),
non-survivals (49.0 (17.9) mg/L), patients with favorable
outcome (75.7 (22.6) mg/L), and those with unfavorable
outcome (52.8 (17.5) mg/L) compared with healthy control
individuals (126.4 (35.4) mg/L, all P < 0.001) (Figure 1).
Correlations of plasma gelsolin level with disease severity
In all 262 patients with aneurysmal SAH, a significant cor-
relation emerged between WFNS scores and plasma gelso-
lin level (r=-0.554, P < 0.001), as well as between Fisher
scores and plasma gelsolin level (r=-0.538, P < 0.001) using
Spearman’s correlation coefficient (Figure 2).
Poor neurologic function prediction
Seventy-three patients (27.9%) suffered from poor neuro-
logic outcome (GOS 1-3) in 6 months. Table 2 shows that
there was a significantly higher likelihood of poor neurolo-
gic outcome at 6 months in patients that have higher
WFNS score, Fisher score, glucose, C-reactive protein,
fibrinogen and D-dimer concentration, and lower gelsolin
level, and that more frequently showed intraventricular
hemorrhage, external ventricular drain, vasospasm, and
CT ischemia. When the above variables found to be signif-
icant in the univariate analysis were introduced into the
logistic model, a multivariate analyses selected WFNS
score (odds ratio, 7.947; 95% confidence interval (CI),
Table 1 The characteristics in patients with aneurysmal
subarachnoid hemorrhage.
All patients (n = 262)
Sex (male/female) 112/150
Age (years) 43.6 ± 12.1
WFNS score on admission 2 (2)
Fisher score on admission 2 (1)
Aneurysmal location
Posterior communication artery 78 (29.8%)
Internal carotid artery 40 (15.3%)
Anterior communication artery 59 (22.5%)
Middle cerebral artery 39 (14.9%)
Anterior cerebral artery 30 (11.5%)
Posterior cerebral artery 10 (3.8%)
Vertebral artery 6 (2.3%)
Surgery 163 (62.2%)
Acute hydrocephalus 79 (30.2%)
Intraventricular hemorrhage 55 (21.0%)
External ventricular drain 91 (34.7%)
Vasospasm 112 (42.8%)
CT ischemia 39 (14.9%)
Admission time (h) 4.0 (4.1)
Plasma-sampling time (h) 5.6 (6.4)
Seizure 37 (14.1%)
Systolic arterial pressure (mmHg) 130 (31)
Diastolic arterial pressure (mmHg) 80 (22)
Mean arterial pressure (mmHg) 98 (24)
Heart rate (beats/min) 80 (35)
Body temperature (°C) 36.5 (0.9)
Respiratory rate (respirations/min) 18 (4)
Blood oxygen saturation (%) 88 (5)
Blood white blood cell count (×109/L) 7.5 (4.2)
Blood hemoglobin level (g/L) 125 (38)
Blood platelet count (×109/L) 174 (52)
Blood glucose level (mmol/L) 9.2 (3.0)
Blood sodium level (mmol/L) 136 (7)
Blood potassium level (mmol/L) 3.7 (0.9)
Prothrombin time (s) 14.6 (4.0)
Thrombin time (s) 18.9 ± 3.2
Partial thromboplastin time (s) 39.4 (10.8)
Plasma C-reactive protein level (mg/L) 6.4 (3.9)
Plasma fibrinogen level (g/L) 3.9 (4.1)
Plasma D-dimer level (mg/L) 1.8 (1.1)
Plasma gelsolin level (mg/L) 66.9 (26.4)
Numerical variables were presented as median (interquartile range) or mean ±
standard deviation. Categorical variables were expressed as counts (percentage).
Numerical variables were analyzed by Mann-Whitney U-test or unpaired Student
t test. Categorical variables were analyzed by chi-square test or Fisher exact test.
n, number of patients; WFNS, World Federation of Neurological Surgeons.
Pan et al. Critical Care 2013, 17:R149
http://ccforum.com/content/17/4/R149
Page 3 of 10
1.398-16.210; P = 0.004), Fisher score (odds ratio, 9.772;
95% CI, 2.278-21.012; P = 0.002), and plasma gelsolin level
(odds ratio, 0.957; 95% CI, 0.933-0.983; P = 0.001) as the
independent predictors for 6-month poor neurologic out-
come of patients.
A ROC curve identified that a baseline plasma gelsolin
level < 63.3 mg/L predicted 6-month poor neurologic out-
come of patients with 80.8% sensitivity and 75.1% specifi-
city (area under curve (AUC), 0.841; 95% CI, 0.791-0.883)
(Figure 3). The predictive value of the gelsolin concentra-
tion was thus similar to those of WFNS score (AUC, 0.894;
95% CI, 0.850-0.929) (P = 0.091) and Fisher score (AUC,
0.886; 95% CI, 0.841-0.922) (P = 0.170). In a combined
logistic-regression model, gelsolin improved the AUC of
WFNS score to 0.930 (95% CI, 0.892 - 0.957) (P = 0.016)
and the AUC of Fisher score to 0.923 (95% CI, 0.884 -
0.952) (P = 0.032).
Mortality prediction
Thirty-one patients (11.8%) died from SAH in 6 months.
Table 3 shows that there was a significantly higher likeli-
hood of death at 6 months in patients that have higher
WFNS score, Fisher score, glucose, C-reactive protein,
fibrinogen and D-dimer concentration, and lower gelsolin
level, and that more frequently showed intraventricular
hemorrhage, external ventricular drain, vasospasm and CT
ischemia. When the above variables found to be significant
in the univariate analysis were introduced into the logistic
model, a multivariate analyses selected WFNS score (odds
ratio, 8.582; 95% CI, 2.028-18.484; P = 0.004), Fisher score
(odds ratio, 9.594; 95% CI, 2.842-22.384; P = 0.003), and
plasma gelsolin level (odds ratio, 0.953; 95% CI, 0.917-
0.990; P = 0.003) as the independent predictors for
6-month mortality of patients.
A ROC curve identified that a baseline plasma gelsolin
level < 52.5 mg/L predicted 6-month mortality of patients
with 71.0% sensitivity and 89.2% specificity (AUC, 0.851;
95% CI, 0.802-0.892) (Figure 4). The predictive value of
the gelsolin concentration was thus similar to those of
WFNS score (AUC, 0.910; 95% CI, 0.869-0.942) (P =
0.146) and Fisher score (AUC, 0.927; 95% CI, 0.889-0.956)
(P = 0.053). In a combined logistic-regression model, gel-
solin improved the AUC of WFNS score to 0.938 (95% CI,
0.902-0.964), and improved the AUC of Fisher score to
0.950 (95% CI, 0.916-0.973), but the differences were not
significant (P = 0.141 and 0.227).
Discussion
In this post hoc analysis of prospective collected data, we
demonstrated that plasma gelsolin levels on admission in
the patients were significantly lower than those in healthy
controls; and in patients who had poor functional outcome
or died in 6 months, the gelsolin levels on admission were
significantly lower compared with levels in survivors or
Figure 1 The change of plasma gelsolin concentration in patients with aneurysmal subarachnoid hemorrhage. Using Mann-Whitney
U-test, the admission gelsolin levels were significantly decreased in all patients, survivals, non-survivals, patients with favorable outcome, and
those with unfavorable outcome compared with healthy control individuals. Data are expressed as median (interquartile range).
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those with good functional outcome. In multivariate logis-
tic regression models of predictors of death and poor
functional outcome, the gelsolin levels on admission were
an independent predictor.
Gelsolin is an 80-kDa actin-binding protein and is the
first and most widely expressed member of a family of
actin-severing proteins, which includes adseverin and villin
[19]. After activation by micromolar Ca2+, gelsolin severs
actin filaments, reducing actin cytoskeleton integrity, and
remains bound to the barbed ends, inhibiting actin fila-
ment extension [20]. Upon reduction in free Ca2+ to less
than micromolar levels, and in the presence of polypho-
sphoinositides, gelsolin is released from the barbed ends,
providing sites for rapid actin filament extension [20].
Thus, gelsolin appears to serve a critical role in actin fila-
ment dynamics [21-24]. Based on its actin-binding prop-
erty, plasma gelsolin has been categorized as part of the
extracellular ‘actin-scavenging’ system that counteracts
actin toxicity when actin is released into the extracellular
space [25]. Accordingly, the degree of plasma gelsolin
depletion should reflect the degree of tissue injury that
may lead to significant exposure of actin to the extracellu-
lar spaces. In every acute tissue injury setting examined,
including toxic, hyperoxic, and idiopathic lung injury,
adult respiratory distress syndrome, acute liver injury,
myonecrosis, pancreatitis, trauma, burns and bacterial and
protozoal sepsis, plasma gelsolin levels are subnormal
[2-11]. The lower the levels of plasma gelsolin, the less
favorable the prognosis of acute illness becomes [8-11].
Overall, gelsolin is associated with the severity and out-
come of critical illness, and therefore, has been proposed
as a prognostic marker in acute illness. Previous studies
have shown significant predictive values of gelsolin in
other acute brain injury including intracerebral hemor-
rhage, ischemic stroke, and traumatic brain injury [12-14].
This study showed that gelsolin was closely related to
WFNS and Fisher scores, which in turn were associated
with outcome of SAH in a multivariate regression model.
Furthermore, gelsolin was identified as a reliable and inde-
pendent marker to predict 6-month outcome in patients
with SAH. Importantly, gelsolin’s discriminative power
(reflected by AUC) was in the range of WFNS and Fisher
scores which are known to be a strong individual outcome
predictor. Gelsolin improved AUC of WFNS and Fisher
scores for functional outcome. However, gelsolin could
not improve AUC of WFNS and Fisher scores for mortal-
ity. Overall, our data suggest that plasma gelsolin level in
this early period might reflect the initial insult (as demon-
strated by the close relation between gelsolin and WFNS
score or Fisher scores) and gelsolin might have an interest-
ing potential as a new prognostic biomarker.
The mechanism of plasma gelsolin’s actions is poorly
understood. Gelsolin was first discovered as an intracellular
protein involved in actin dynamics [26]. Plasma gelsolin
was subsequently identified as a secreted isoform of the
cytoplasmic gelsolin [27]. Similar to cytoplasmic gelsolin,
plasma gelsolin also severs and scavenges actin [28-30], a
major body protein that may be exposed or released by cel-
lular injury and that may enhance some major components
of proinflammatory cytokine production, and impair the
microcirculation and compromise multiple organs [31,32].
In addition to actin, plasma gelsolin binds and modulates
bioactive lipids, such as endotoxin [33], lysophosphatidic
acid [34], and platelet activating factor [35]. This effect may
partially explain how exogenous gelsolin replacement sig-
nificantly enhances survival of septic animals [8], and
blunts the inflammatory response in animal models of lung
injury [36] and burns [7]. Based on these data, we propose
that plasma gelsolin functions as an important endogenous
guard against overwhelming inflammation from tissue
injuries.
Gelsolin is constitutively expressed throughout the cen-
tral nervous system and is particularly concentrated in
Figure 2 The correlations of plasma gelsolin level with disease
severity in patients with aneurysmal subarachnoid hemorrhage.
Plasma gelsolin level was highly associated with WFNS score and
Fisher score using Spearman’s correlation coefficient. WFNS indicates
World Federation of Neurological Surgeons.
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neuronal growth cones [37]. It has been demonstrated
that gelsolin modulates voltage-dependent Ca2+ channels
and N-methyl-D-aspartate receptor-coupled channel
activity and reduces vulnerability to excitotoxicity in cul-
tured hippocampal neurons after its activation by Ca2+
[38] and that gelsolin -/- mice are more susceptible to
brain injury after ischemia/reperfusion and gelsolin could
serve as a neuroprotective factor in murine cerebral ische-
mia [39]. Recent results suggested that enhanced gelsolin
expression is an important mechanism by which histone
deacetylase inhibitor trichostatin A protects against
ischemic brain injury [40]. A recent paper reported plasma
gelsolin is decreased and correlated with rate of decline in
Alzheimer’s disease [41]. From the available information,
Table 2 The factors associated with 6-month function outcome in patients with aneurysmal subarachnoid hemorrhage.
GOS 1-3 (n = 73) GOS 4-5 (n = 189) Univariate analysis P value
Sex (male/female) 34/39 78/111 0.463
Age (years) 44.5 ± 10.5 43.2 ± 12.7 0.847
WFNS score on admission 3 (1) 2 (2) < 0.001
Fisher score on admission 4 (1) 2 (1) < 0.001
Aneurysmal location 0.761
Posterior communication artery 27 (37.0%) 51 (27.0%)
Internal carotid artery 11 (15.1%) 29(15.3%)
Anterior communication artery 15 (20.5%) 44 (23.3%)
Middle cerebral artery 10 (13.7%) 29 (15.3%)
Anterior cerebral artery 6 (8.2%) 24 (12.7%)
Posterior cerebral artery 2 (2.7%) 8 (4.2%)
Vertebral artery 2 (2.7%) 4 (2.1%)
Surgery 46 (63.0%) 117 (61.9%) 0.868
Acute hydrocephalus 39 (53.4%) 40 (21.2%) < 0.001
Intraventricular hemorrhage 44 (60.3%) 11 (5.8%) < 0.001
External ventricular drain 51 (69.9%) 40 (21.2%) < 0.001
Vasospasm 56 (76.7%) 56 (29.6%) < 0.001
CT ischemia 20 (27.4%) 19 (10.1%) < 0.001
Admission time (h) 4.0 (3.5) 4.0 (4.7) 0.259
Plasma-sampling time (h) 5.4 (5.6) 5.6 (6.6) 0.204
Seizure 14 (19.2%) 23 (12.2%) 0.144
Systolic arterial pressure (mmHg) 129 (34) 131 (30) 0.748
Diastolic arterial pressure (mmHg) 79 (18) 81 (24) 0.706
Mean arterial pressure (mmHg) 98 (20) 97 (25) 0.530
Heart rate (beats/min) 81 (34) 79 (35) 0.716
Body temperature (°C) 36.4 (1.6) 36.5 (0.9) 0.381
Respiratory rate (respirations/min) 19 (3) 18 (4) 0.150
Blood oxygen saturation (%) 88 (5) 89 (5) 0.795
Blood white blood cell count (×109/L) 7.8 (5.8) 7.4 (3.7) 0.607
Blood hemoglobin level (g/L) 124 (36) 125 (39) 0.409
Blood platelet count (×109/L) 173 (43) 174 (56) 0.863
Blood glucose level (mmol/L) 10.4 (4.6) 8.9 (2.4) < 0.001
Blood sodium level (mmol/L) 136 (8) 136 (8) 0.916
Blood potassium level (mmol/L) 3.7 (1.0) 3.7 (0.9) 0.904
Prothrombin time (s) 14.2 (4.0) 14.8 (4.1) 0.601
Thrombin time (s) 18.8 ± 3.2 18.9 ± 3.2 0.942
Partial thromboplastin time (s) 40.3 (11.2) 39.3 (10.8) 0.332
Plasma C-reactive protein level (mg/L) 8.0 (5.9) 6.1 (3.3) < 0.001
Plasma fibrinogen level (g/L) 5.3 (4.4) 3.7 (3.2) 0.001
Plasma D-dimer level (mg/L) 2.1 (1.6) 1.7 (1.0) 0.003
Plasma gelsolin level (mg/L) 52.8 (17.5) 75.7 (22.6) < 0.001
Numerical variables were presented as median (interquartile range) or mean ± standard deviation. Categorical variables were expressed as counts (percentage).
Numerical variables were analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test.
GOS, Glasgow outcome scale; n, number of patients; WFNS, World Federation of Neurological Surgeons.
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Figure 3 ROC curve analysis of plasma gelsolin concentration for identifying patients with 6-month unfavorable outcome. ROC curves were
constructed based on the sensitivity and specificity of the plasma gelsolin concentration for identifying 6-month unfavorable outcome. The AUC was
calculated based on the ROC curves and expressed as 95% CI. AUC ranges from 0.5 to 1.0. An AUC closer to 1 indicates a higher predictive power.
Table 3 The factors associated with 6-month mortality in patients with aneurysmal subarachnoid hemorrhage.
Non-survival group (n = 31) Survival group (n = 231) Univariate analysis P value
Sex (male/female) 13/18 99/132 0.922
Age (years) 44.4 ± 12.0 43.5 ± 12.2 0.695
WFNS score on admission 4 (1) 2 (2) < 0.001
Fisher score on admission 4 (1) 2 (1) < 0.001
Aneurysmal location 0.974
Posterior communication artery 7 (22.6%) 71 (30.7%)
Internal carotid artery 6 (19.4%) 34 (14.7%)
Anterior communication artery 7 (22.6%) 52 (22.5%)
Middle cerebral artery 5 (16.1%) 34 (14.7%)
Anterior cerebral artery 4 (12.9%) 26 (11.3%)
Posterior cerebral artery 1 (3.2%) 9 (3.9%)
Vertebral artery 1 (3.2%) 5 (2.2%)
Surgery 20 (64.5%) 143 (61.9%) 0.778
Acute hydrocephalus 20 (64.5%) 59 (34.2%) < 0.001
Intraventricular hemorrhage 27 (87.1%) 28 (12.1%) < 0.001
External ventricular drain 28 (90.3%) 63 (27.3%) < 0.001
Vasospasm 28 (90.3%) 84 (36.4%) < 0.001
CT ischemia 12 (38.7%) 27 (11.7%) < 0.001
Admission time (h) 4.0 (6.0) 4.0 (4.0) 0.826.
Plasma-sampling time (h) 6.0 (7.4) 5.4 (6.4) 0.398
Seizure 7 (22.5%) 30 (13.0%) 0.174
Systolic arterial pressure (mmHg) 130 (36) 130 (30) 0.373
Diastolic arterial pressure (mmHg) 81 (21) 80 (22) 0.421
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it is suggested that reversing plasma gelsolin deficiency
may be an effective treatment for SAH.
In addition, univariate analysis showed that some para-
meters including blood glucose level, plasma C-reactive
protein level, plasma fibrinogen level, and plasma D-dimer
level were associated with 6-month poor functional out-
come and mortality. But, a multivariate logistic regression
did not verify these results. These differences may be
caused by sample size or study design. However, this can
supply some information about potentials of these biomar-
kers such as blood glucose level, plasma C-reactive protein
level, plasma fibrinogen level, and plasma D-dimer level as
outcome predictors in aneurysmal SAH.
Conclusions
In this study, gelsolin levels are associated with clinical
severity and are a useful, complementary tool to predict
functional outcome and mortality 6 months after aneurys-
mal subarachnoid hemorrhage.
Key messages
- In the patients with aneurysmal subarachnoid
hemorrhage, plasma gelsolin level on admission was
substantially lower than that in healthy controls.
- Plasma gelsolin level was highly negatively associated
with World Federation of Neurological Surgeons score
and Fisher score after aneurysmal subarachnoid
hemorrhage.
Table 3 The factors associated with 6-month mortality in patients with aneurysmal subarachnoid hemorrhage.
(Continued)
Mean arterial pressure (mmHg) 101 (23) 97 (25) 0.257
Heart rate (beats/min) 81 (23) 80 (36) 0.602
Body temperature (°C) 36.7 (1.9) 36.5 (0.9) 0.551
Respiratory rate (respirations/min) 19 (3) 18 (5) 0.935
Blood oxygen saturation (%) 88 (7) 88 (5) 0.344
Blood white blood cell count (×109/L) 6.5 (6.1) 7.5 (4.0) 0.566
Blood hemoglobin level (g/L) 122 (37) 125 (37) 0.129
Blood platelet count (×109/L) 183 (34) 173 (56) 0.269
Blood glucose level (mmol/L) 10.7 (5.9) 9.1 (2.6) 0.003
Blood sodium level (mmol/L) 135 (11) 136 (7) 0.673
Blood potassium level (mmol/L) 3.8 (1.3) 3.7 (0.9) 0.926
Prothrombin time (s) 14.5 (3.2) 14.6 (4.1) 0.659
Thrombin time (s) 18.4 ± 2.9 18.9 ± 3.3 0.369
Partial thromboplastin time (s) 39.5 (11.8) 39.4 (10.6) 0.476
Plasma C-reactive protein level (mg/L) 8.1 (6.5) 6.2 (3.6) 0.013
Plasma fibrinogen level (g/L) 4.8 (4.2) 3.9 (3.8) 0.036
Plasma D-dimer level (mg/L) 2.3 (1.2) 1.8 (1.1) 0.014
Plasma gelsolin level (mg/L) 49.0 (17.9) 70.3 (25.5) < 0.001
Numerical variables were presented as median (interquartile range) or mean ± standard deviation. Categorical variables were expressed as counts (percentage).
Numerical variables were analyzed by Mann-Whitney U-test or unpaired Student t test. Categorical variables were analyzed by chi-square test or Fisher exact test.
n, number of patients; WFNS, World Federation of Neurological Surgeons.
Figure 4 ROC curve analysis of plasma gelsolin concentration
for identifying patients with 6-month mortality. ROC curves
were constructed based on the sensitivity and specificity of the
plasma gelsolin concentration for identifying 6-month mortality.
The AUC was calculated based on the ROC curves and expressed as
95% CI. AUC ranges from 0.5 to 1.0. An AUC closer to 1 indicates a
higher predictive power.
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- Plasma gelsolin level was an independent predictor
of poor long-term functional outcome and death
6 months after aneurysmal subarachnoid hemorrhage.
- Plasma gelsolin level was a useful, complementary
tool to predict poor long-term functional outcome and
mortality 6 months after aneurysmal subarachnoid
hemorrhage.
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